Cas No.Product NameDescription
220127-57-1Imatinib mesylateImatinib mesylate is a small molecule that inhibits the c-Abl protein-tyrosine kinase, a kinase specifically important for proliferation of chronic myelogenous leukemia .
1089283-49-7GSK1904529AGSK1904529A, which potently inhibits IGF-IR (IC50= 27 nmol/L) and IR (IC50= 25 nmol/L) activities in vitro and in vivo, is a promising candidate for therapeutic use in solid and hematologic cancers.
796967-16-3LinifanibLinifanib (ABT-869) is a structurally novel, potent RTK and VEGF and PDGF receptor families inhibitor with IC50 of 0.2, 2, 4, and 7 nM for human endothelial cells, PDGFR-β, KDR, and CSF-1R, respectively.
379231-04-6AZD0530Saracatinib (AZD0530) is a highly selective, orally available, dual-specific Src/Abl kinase inhibitor with IC50 of 2.7 and 30 nM for c-Src and Abl kinase, respectively.
1146699-66-2BMS-708163BMS-708163 is a γ-secretase inhibitor (GSI) (IC50 =0.3 nM).
873837-23-1BMS-599626 HClBMS-599626 (BMS-599626; AC480) is a highly selective pan-HERKinase inhibitor with IC50 of 20 and 30 nM for the inhibition of HER1and HER2, respectively.
790299-79-5MasitinibMasitinib also known as Masivet, AB1010 is a tyrosine kinase, c-Kit, PDGFR, FGFR3, the FAK pathway inhibitor with IC50 of 150 ± 80, 200 ± 40 nM.
867160-71-2LinsitinibLinsitinib is highly potent, orally efficacious and highly selective, dual ATP-competitive tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) (IC50: 35 nM) and insulin receptor (IR) (IC50: 75 nM).
383432-38-0CP-724714CP-724714 is a HER-2 tyrosine kinase inhibitor, IC50 of 15 ng/ml.
850879-09-3AmuvatinibMP470 is a multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Met, c-Kit, PDGFRalpha, Flt3, and c-Ret and with an IC50 of median 5 μM.
943319-70-8PonatinibPonatinib (AP24534) is a novel potent, orally available small molecule multitargeted kinase inhibitor with IC50 of 0.37, 2, 1.5, 2.2, 1.1, 1and 0.24 nM for native pan-BCR-ABL, mutated form, VEGFR2, FGFR1, PDGFRα, mutant FLT3 phosphorylation and LYN.
728033-96-3OSI-930OSI-930 is an inhibitor of the receptor tyrosine kinases c-Kit (IC50:9.5nM) and VEGFR-2 (IC50:10.1nM).
1025720-94-8BMS-777607BMS-777607, a Met tyrosine kinase inhibitor.
1174046-72-0BMS-794833BMS 794833 is a potent ATP competitive inhibitor of Met (IC50 = 1.7 nM) and Flk-1 (IC50 = 15 nM).
940310-85-0NVP-BHG712NVP-BHG712 is a small molecule specific EphB4, VEGFR2, c-raf, c-src and c-Abl kinase inhibitor with ED50 of 25 nM, 4.2, 0.4, 1.3 and 1.7μM, respectively.
219580-11-7PD173074PD173074 is a potent ATP-competitive, reversible FGFR and VEGFR inhibitor with IC50 of 5, 21.5 and ~100 nM for FGFR3, FGFR1 and VEGFR2, respectively.
875337-44-3MGCD-265MGCD-265 is a multi-targeted kinase inhibitor, which targets the c-MET, VEGFR1, VEGFR2, VEGFR3, Tie-2 and Ron receptor tyrosine kinases.
475489-16-8NVP-AEW541NVP-AEW541 is an IGF-IR inhibitor with an IC50 of median 3.6 μM.
936091-14-4TG101209TG101209 is a potent and small molecule JAK2-selective kinase inhibitor with IC50 of 6, 25, 17 and 169 nM for JAK2, FLT3, RET and JAK3, respectively.
811803-05-1ApatinibApatinib (YN968D1) is a novel, orally bioavailable, selective inhibitor with potential antiangiogenic and antineoplastic activities.

First Previous Next End   Jump to  Page
Cell Cycle/Checkpoint
Angiogenesis/Tyrosine Kinase
Apoptosis Pathway
Aurora/Ksp Pathway
MAPK Pathway
Hormone Pathay
Proteases/HSP90/HSP70 Pathway
Wnt/Hedgehog/Notch Pathway
Jak/Stat Pathway
Ca/cAMP/Lipid Signaling Pathway
Neuro Signaling Pathway
TGF-beta/Smad Signaling Pathway
GPCR Pathway
Ion channel Pathway
Cytochrome P450 Pathway
Others Pathway